Since anti-OX40 was able to increase the frequency of the DP CD8+ TIL subset in the immunologic responder patients, we hypothesize that the increased frequency of the tumor-reactive T cells after treatment aids in tumor clearance and protection from recurrence (as demonstrated by survival benefit in Fig. 4a, b). This evidence concerns the gene CD8A and neoplasm.